Measles, Mumps and Rubella Vaccine, Live
Trade name: Priorix
Approved
Jun 3, 2022
The MMR vaccine is a vaccine against measles, mumps, and rubella. The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least four weeks between the doses. After two doses, 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella. The vaccine is also recommended for those who do not have evidence of immunity, those with well-controlled HIV/AIDS, and within 72 hours of exposure to measles among those who are incompletely immunized. It is given by injection. — Wikipedia
Clinical trial activity
17 trials · 15 clinical orgs · 1 marketing orgs
Earliest trial started Sep 1, 2005 (NCT00226499)
Timeline
2000s
- Jan 1, 2005
GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)
- Jan 1, 2007
GlaxoSmithKline — Earliest Phase 2 Sponsor(trial)
2020s
- Jun 3, 2022
GlaxoSmithKline — Earliest FDA Approval
- Jun 3, 2022
GlaxoSmithKline — NDA Organization
Indications
Approved for
Studied for
- BCG Vaccine · Phase 4
- Chickenpox · Phase 3
- Chikungunya Fever · Phase 2
- Diphtheria · Phase 3
- Haemophilus influenzae type b · Phase 3
- Healthy Volunteers · Phase 3
- Herpes Zoster Vaccine · Phase 3
- Immunity · Phase 4
- Measles · Phase 3
- Measles-Mumps-Rubella Vaccine · Phase 3
- Meningococcal Infections · Phase 3
- Mumps · Phase 3
- Neisseria meningitidis · Phase 3
- Papillomavirus Infections · Phase 3
- Pertussis Vaccine · Phase 3
- Pneumonia · Phase 3
- Poliomyelitis · Phase 3
- Rubella · Phase 3
- Tetanus · Phase 3
- Vaccines · Phase 4
Mechanism of action
- Unspecified targetImmunity, active
Immunity, active
- Mumps virusImmunity, active
Mumps virus immunity, active
- Measles virusImmunity, active
Measles virus immunity, active
Approval history
- approvedJun 3, 2022
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMMR vaccine ↗
Also known as
- gsk208136
- priorix
- priorix-tetra
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06824181 | Phase 3 | Feb 27, 2025 | Sanofi |
| NCT06824194 | Phase 3 | Feb 18, 2025 | Sanofi |
| NCT06399003 | Phase 3 | Jun 28, 2024 | China National Biotec Group Co., Ltd |
| NCT05794230 | Phase 3 | Mar 27, 2023 | Sanofi-Aventis |
| NCT02861586 | Phase 2 | Aug 1, 2016 | ABF Pharmaceutical Services GmbH, Assign Clinical Research GmbH, Batavia Biosciences, Biofabri, S.L, Envigo Pharma Consulting Limited, Medical University of Graz, SRI International, Themis Bioscience GmbH, University of Rostock, University of Vienna |
| NCT02002156 | Phase 4 | Jun 1, 2014 | University of Oxford |
| NCT01627561 | Phase 3 | Oct 1, 2012 | GlaxoSmithKline |
| NCT01506193 | Phase 3 | Feb 1, 2012 | GlaxoSmithKline |
| NCT01245049 | Phase 3 | Apr 1, 2011 | GlaxoSmithKline |
| NCT00969436 | Phase 3 | Nov 1, 2009 | GlaxoSmithKline |
| NCT00892775 | Phase 2 | Jun 3, 2009 | GlaxoSmithKline |
| NCT00871000 | Phase 3 | Apr 1, 2009 | GlaxoSmithKline |
| NCT00751348 | Phase 3 | Oct 1, 2008 | GlaxoSmithKline |
| NCT00578175 | Phase 2 | Nov 1, 2007 | GlaxoSmithKline |
| NCT00474266 | Phase 3 | Jun 1, 2007 | GlaxoSmithKline |
| NCT00326118 | Phase 3 | Jun 1, 2006 | GlaxoSmithKline |
| NCT00226499 | Phase 3 | Sep 1, 2005 | GlaxoSmithKline |
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 11 | 11 | 2 | 2005 |
| Sanofi | For profit | 2 | 2 | 1 | 2025 |
| ABF Pharmaceutical Services GmbH | For profit | 1 | 0 | 1 | 2016 |
| Assign Clinical Research GmbH | For profit | 1 | 0 | 1 | 2016 |
| Batavia Biosciences | For profit | 1 | 0 | 1 | 2016 |
| Biofabri, S.L | For profit | 1 | 0 | 1 | 2016 |
| China National Biotec Group Co., Ltd | For profit | 1 | 1 | 1 | 2024 |
| Envigo Pharma Consulting Limited | For profit | 1 | 0 | 1 | 2016 |
| Medical University of Graz | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Sanofi-Aventis | For profit | 1 | 1 | 1 | 2023 |
| SRI International | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Themis Bioscience GmbH | For profit | 1 | 1 | 1 | 2016 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Rostock | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2016 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | NDA | Jun 3, 2022 |